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Background: Attention-deficit hyperactivity disorder (ADHD) is highly prevalent amongst prison inmates and the
criminal justice system (CJS) likely bears considerable costs for offenders with ADHD. We aimed to examine the
relationship between ADHD and health-related quality of life (HRQoL) and quality-adjusted life years (QALY)
amongst imprisoned adults; and to estimate the annual expenditure associated with ADHD status in prison.
Methods: An observational study was performed in 2011–2013, at Porterfield Prison, Inverness, United Kingdom
(UK). The all male sample included 390 adult prison inmates with capacity to consent and no history of moderate
or severe intellectual disability. Participants were interviewed using the Diagnostic Interview for ADHD in Adults 2.0.
The Health Utilities Index Mark 3 (HUI3) was used to measure health status, and to calculate attribute specific
HRQoL scores and QALY. Health service utilisation was obtained through inspection of medical prison records.
Inmates with ADHD were compared with inmates without ADHD.
Results: Inmates with ADHD had significantly lower QALYs, with a clinically significant adjusted difference of 0.13.
Psychiatric co-morbidity accounted for the variation of ADHD on the HUI3 emotion domain only. Medical costs for
inmates with ADHD were significantly higher; and behaviour-related prison costs were similar to prisoners without
ADHD, reflecting a low frequency of recorded critical incidents.
Conclusions: ADHD may directly contribute to adverse health and quality of life through cognitive and executive
function deficits, and co-morbid disorders. The extrapolation of conservative cost estimates suggests that the
financial burden of medical and behavior-related prison care for inmates with ADHD in the UK is approximately
£11.7 million annually. The reported cost estimates are conservative as there is great variability in recorded critical
incidents in prisons. In turn, for some prison establishments the prison care costs associated with prisoners with
ADHD may be considerably greater.
Keywords: ADHD, Health-related quality of life, Economic evaluation, Quality-adjusted life years, Prison, CostsBackground
Among the general population attention-deficit hyper-
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disorder [3] often persisting into adulthood. It is one of
the most common mental health disorders in children
with recent prevalence estimates ranging between 5.9
and 7.1% [4, 5]. There is recent evidence suggesting
late-onset of ADHD, which will require research to bet-
ter understand its implication [6, 7]. Clinically significant
symptoms persist beyond childhood in 65% of cases [8],
and may affect as much as 2.8–5.3% of adults worldwide
[9, 10]. Its substantial burden of disease is evidenced by
an increased likelihood for serious accidents [11], earlier
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ADHD confers significant impairment [15], and reduced
quality of life [16] to those afflicted by it. It is also
highly prevalent amongst prison inmates, with a
meta-analytical prevalence estimate of 25.5% [17].
Prison inmates with ADHD are reported to be at
significant risk for having increased psychiatric
co-morbidity and poorer psychosocial adjustment to
the prison environment [18–21].
Health economic evaluations have become an essential
part of research and provide evidence supporting health
interventions [22]. ADHD is consistently linked with
substantially elevated costs and with significant eco-
nomic burden on education [23] and health [2]. Annual
service costs linked with ADHD are reportedly £670 mil-
lion in the UK [24]. Meanwhile, annual ADHD-related
healthcare costs are estimated between $21 to $44 bil-
lion in the United States [23]. Furthermore, in the US
costs associated with accident claims are more than
three times higher in adults with ADHD [1].
Despite the disproportionate representation of ADHD
within the prison population, the health-related quality
of life (HRQoL) and related costs remains unknown.
In this study we aim to examine the impact of ADHD
amongst imprisoned adults. We set out to determine
prisoners’: 1) scope and extent of impaired HRQoL
utility scores and quality-adjusted life years (QALY) and
2) service use and costs attributable to ADHD.
Methods
Participants and sample selection
Following approval from the Scottish Prison Service
Research Access and Ethics Committee and in accord-
ance with the Declaration of Helsinki written consent
was obtained by prisoners who were recruited by oppor-
tunity sampling from Porterfield Prison, Inverness,
Scotland, UK, over a period of 18 months in 2011–2013.
Participants included 390 adult male prisoners who
consented to participate. Those with moderate or severe
learning difficulties, lack of fluency in the English lan-
guage, and severe mental illness (as judged by prison
officers) were excluded from participating.
Participants in the study were indirectly compensated.
The study group deposited £20 per participant into a
Prison Common Good Fund, which was managed by a
group of prisoners. The fund was then used to purchase
items for the common good of all prisoners to enhance
prison life.
Prisoners who indicated interest attended an appoint-
ment with the researcher where they were given detailed
oral and written information about the study and the
consent procedures. After obtaining written consent,
researchers administered a comprehensive battery of
measures, which took approximately 4 h to complete(usually split across 2 or 3 sessions). The researchers re-
ceived comprehensive training to administer the
measures from the Maudsley Hospital Adult ADHD
Service. Further details about the comprehensive battery
of measures have been published elsewhere [25].
Data related to medical service use were gathered
through inspection of prison medical records and
medical costs were calculated based on reference costs
reported by the (NHS; see details below). Data related to
behavioural disturbance incidents were gathered through
inspection of prison records and related costs were
calculated based on similar reference costs and were
reported as prison costs (see details below).Measures
Health utilities index mark 3 (HUI3)
The HUI3 is a multi-attribute health status classification
system that enables researchers to map levels in the fol-
lowing categories: vision, hearing, speech, ambulation,
dexterity, emotion, cognition, and pain; using decision
tables and coding algorithms, which can be represented
in terms of attribute specific HRQoL scores [26, 27].
HRQoL refers to the value assigned to life span when
considering impairments and functional states that may
be affected by disease, injury, and treatment [28]. The
HUI3 scoring system provides HRQoL utility scores ran-
ging from 0.00 (dead) to 1.00 (perfect health), and meets
criteria for calculating QALY [26]. Prisoners’ were asked
to answer HUI3 questions based upon their health status
in the 4 weeks prior to the interview. The HUI3
composite score was used to calculate QALY and was
extrapolated to 1 year to represent the study health
evaluation time frame, as previously applied on
cost-effectiveness studies [29]. Estimating beyond this
time frame would have introduced a very high degree
of uncertainty in estimates.ADHD diagnosis
All participants underwent a comprehensive evaluation
for ADHD and were interviewed using the Diagnostic
Interview for ADHD in Adults 2.0 (DIVA-2) [30]. The
DIVA-2 is a validated semi-structured clinical interview
used to diagnose ADHD in adults based on the 5th edi-
tion of Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) criteria [3]; and has been used in
clinical [31] and law enforcement settings [32]. Ques-
tions addressed their current and childhood (ages 5 to
12) presentation of ADHD symptoms and scope of
impairment.
Participants were also questioned whether they were
previously diagnosed or treated for ADHD or any other
psychiatric illness.
Young et al. BMC Psychiatry  (2018) 18:210 Page 3 of 11Brief symptom inventory (BSI)
The Brief Symptom Inventory (BSI) is a brief psycho-
logical self-report scale [33]. The BSI has 9 subscales
(Somatization, Obsession-compulsion, Interpersonal sen-
sitivity, Depression, Anxiety, Hostility, Phobic anxiety,
Paranoid ideation and Psychoticism), and 3 composite
measures (Global Severity Index, Positive Symptom Dis-
tress Index, and Positive Symptom Total). We used the
BSI depression and anxiety measures as covariates in our
health evaluation models because they represent common
mental health conditions.
Medical service use and costs
Detailed medical service utilization history was obtained
through inspection of participants prison medical
records. Data from prisoners’ medical charts (covering
the 3 months prior to the appointment with the re-
searcher) were abstracted, verified, and entered into a
database for analyses. The authors chose to include 3
months of service for practical reasons; and additionally
thought this time period fairly represented the medical
service use of all prisoners given the variance in prison
stays. Data included details from appointments with a
general practitioner, physical health nurse, mental health
nurse, addiction services nurses, or any other type of
nurse, psychiatrist, psychologist, podiatrist, oral health
practictioner, or any other type of health related visit
such as Well-man clinic or other health clinics, and hos-
pital outpatient visit. Medical costs for these appoint-
ments were calculated according to reference costs
reported by the NHS Trust [34]. Medication costs were
not explicitly collected in the study.
Prison service use and costs
Prisoners’ behavioural disturbance incidents were ob-
tained from prison records. Reports of non-attendance
to prison activities, being under observation, number of
adjudications, and critical incidents were collected and
used to calculate the related prison costs. Prison costs
were calculated based upon reference costs from the UK
Ministry of Justice and HM Prison Service [35], Social
Research Unit, Dartington [36], and from direct commu-
nication with Scottish Prison Service management.
All reported costs were in Pounds Sterling (£) for the
years 2012–2015, and adjusted using the Consumer
Price Index (CPI, 2016).
Analytical strategy
Frequencies were reported for all categorical variables,
and means with their standard deviation for continuous
variables. The median and inter-quartile range was used
for all cost related values.
Because of the HUI3 utility scores’ interval properties,
we used t-tests for unadjusted analyses. To estimate theassociation between ADHD and HUI3 single attribute
and composite utility scores, Type I Tobit models were
used in favour of traditional ordered logistic regression
models. A Tobit model is designed to estimate linear
relationships between variables when there are ceiling or
flooring effects on the outcome [37]. Ignoring the
censoring and fitting regression models estimated using
OLS would have been systematically biased toward the
null hypothesis, whereby type II error is increased. HUI3
single attribute and composite utility scores with the
value of one are considered censored.
Considering the highly skewed nature of cost variables
we used generalised linear models (GLM) with a gamma
distribution and log-link function. This way the natural
log is modeled and then the predicted margins are calcu-
lated in order to obtain the cost differential for those
with ADHD [38]. All cost models were adjusted only for
age. HUI3 includes an emotion domain that may be
sensitive to coexisting disorders (in addition to ADHD).
Therefore, models for all HUI3 variables were further
adjusted for co-morbid anxiety and depression standard-
ized symptom scores.
We established a significance level at p ≤ 0.05 for all
statistical tests. All analyses were performed using Stata
version 13 (StataCorp) [39].
Results
Descriptive statistics
The all male sample was essentially Caucasian British
(99.0%) with an average age of 30.3 years (sd 8.3). Pris-
oners with ADHD had a significantly lower mean age
than those without ADHD (28.2 years (sd 7.5) vs.
31.0 years (sd 8.5,) p < 0.01). 18.8% (18/96) prisoners
with ADHD reported a prior diagnosis of ADHD and
15.6% (15/96) reported having ever received pharmaco-
logical treatment for ADHD.
Out of the total sample of 390 participants, 81 (20.8%)
required assistance with reading the questionnaires. For
those diagnosed with ADHD, 31/96 (32.3%) required as-
sistance in contrast to 50/294 (17.0%) of the other par-
ticipants. This difference is significant (Chi2 (df 1) = 10.2,
p = 0.001; Odds Ratio = 2.3, Confidence Interval 1.3–3.9).
Health status
Table 1 includes the mean and distribution of all HUI3
specific attributes and composite HRQoL utility scores
for all inmates. Prisoners’ variability noticeably increased
in scores for emotion, cognition, pain, and HRQoL.
Independent sample t-tests were estimated for all util-
ity scores and HRQoL (Table 2) comparing prisoners
with ADHD with prisoners without ADHD. Inmates
with ADHD had significantly lower scores in the follow-
ing categories: speech (p < 0.05), ambulation (p < 0.01),
emotion (p < 0.001), cognition (p < 0.001), pain (p < 0.05),
Table 1 Distribution of HUI3 Specific Attribute Utility Scores for
all Inmates
HUI3 Attributes, N = 390 n Mean score Standard deviation
Vision 385 0.989 (0.024)
Hearing 387 0.989 (0.061)
Speech 390 0.966 (0.073)
Ambulation 389 0.991 (0.072)
Dexterity 390 0.985 (0.078)
Emotion 370 0.787 (0.274)
Cognition 390 0.837 (0.237)
Pain 390 0.854 (0.278)
HRQoL 362 0.647 (0.307)
Notes: HUI3 data covered the 4 weeks prior to interview
Cost per unit is defined as cost per inmate for each visit. Median medical costs
were calculated from data collected from medical records covering the
3 months prior to interview
aIncludes Hepatitis C, Harm reduction, and Smoking cessation nursing staff
bIncludes any other recorded health visits, e.g. Well-man clinic
cIncludes all missed prison therapeutic and other activities per inmate
dCalculated by time spent and number of prison staff involved (based on
average hourly pay rate)
eCalculated by time spent and number of prison staff involved in any
adjudication process (estimated 15 min. Per process)
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distribution of HRQoL utility scores comparing pris-
oners without ADHD with those with ADHD.
Table 3 demonstrates that even after adjustment for
age, anxiety, depression, and/or without correction for
missing values, that censored Tobit models were signifi-
cant in each adjusted model for vision, ambulation, emo-
tion, cognition, and QALY. The inclusion of anxiety and
depressive disorders in models 2 and 3, attenuated the
associations with emotion, hearing, and pain attributes.
Attenuation of the association with hearing and pain
should be interpreted with caution, as their un-
adjusted effect sizes were small. Models 2 and 3 show
that prisoners with ADHD have a significant differ-
ence in QALY of 0.13 and 0.10, compared to those
without ADHD.Table 2 HUI3 Attribute Utility Scores by ADHD Group (n = 96 ADHD
HUI3 Attributes No ADHD
Mean score
ADHD
Mean score
Vision 0.991 0.986
Hearing 0.992 0.979
Speech 0.971 0.952
Ambulation 0.997 0.974
Dexterity 0.984 0.986
Emotion 0.817 0.692
Cognition 0.879 0.709
Pain 0.874 0.792
HUI3 Composite HRQoL 0.699 0.47725% of all participants had missing values by endorsing
‘Don’t Know’ on several questions of the HUI3. Patterns
of missing values were analysed and the most plausible
values were imputed using a technique developed by
Naeim and colleagues specifically for HUI-3 scores [40].
All 41 questions of the HUI-3 instrument allow
respondents to answer ‘Don’t Know’. Because there are
no instructions in the instrument manual for how to
manage or score these answers, the ‘Don’t Know’ cat-
egory interferes with the scoring leading to substantial
amounts of missing data. Common methods for imput-
ing data in this scenario may not be as effective or can
even be misleading, given that answers to other ques-
tions within the same domain (e.g. vision) often help
identify a sole correct answer to those marked as ‘Don’t
Know’. The well cited imputation method by Naeim
et al. [40] advises inspecting each possible change in at-
tribute score for every answer to the ‘Don’t Know’ miss-
ing value, then selecting the most plausible value
accordingly.
Furthermore, we performed a sensitivity analysis based
only on those with complete HUI3 data to examine any
differences in estimates before and after using the in-
spection and deduction method to account for ‘Don’t
Know’ answers.
Service utilization and costs
Table 4 includes all cost model inputs for the total me-
dian associated medical and prison costs for all inmates.
Table 5 shows that in terms of medical service utilisa-
tion, prisoners with ADHD visited significantly more
general practitioners (p < 0.05), physical health nurses (p
< 0.05), and mental health nurses (p < 0.01) in the
three-month period assessed. No significant associations
were observed for any other health services.
Table 6 shows that age adjusted medical costs were
significantly greater among inmates with ADHD (p <
0.05), but prison costs were not. Cost items were
assessed based on a 3 month window, then calculated, n = 294 non-ADHD)
t Effect size (d) p
1.839 0.218 0.067
1.938 0.229 0.053
2.20 0.259 0.028
2.71 0.319 0.007
−0.113 −0.013 0.910
3.83 0.466 < 0.001
6.41 0.753 < 0.001
2.52 0.296 0.012
6.15 0.759 < 0.001
Fig. 1 Distribution of HUI3 Composite HRQoL scores by ADHD group: A greater proportion of inmates without ADHD have HUI composite
HRQoL scores above 0.7. There is a greater amount of variability in the HUI composite HRQoL scores among inmates with ADHD
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utilisation and behaviour in prison. Total medical and
prison costs for inmates with ADHD were £ 590 more
per year than for inmates without ADHD.
Discussion
HUI3 health attributes and QALY
To the best of our knowledge, our study is the first ad-
dressing ADHD health status using HUI3 amongst
prison inmates. Previous studies documented the rela-
tionship between symptom severity and poorer HRQoL,Table 3 Adjusted Regression Models for HUI3 Attribute Utility Score
ADHD; (n = 96 ADHD, n = 294 non-ADHD)
Model 1
HUI3 attributes Beta coef. (se)
Vision −0.04 (0.01)**
Hearing − 0.48 (0.22)*
Speech −0.08 (0.04)
Ambulation −0.51 (0.23)*
Dexterity − 0.06 (0.11)
Emotion −0.19 (0.04)***
Cognition −0.29 (0.05)***
Pain − 0.15 (0.07)*
QALY derived by HUI3a −0.25 (0.04)***
Note. The first two columns refer to Tobit models using data that was corrected for
which we fitted a similar Tobit model but using only available data without accoun
aAll tobit models to account for censoring at the upper level of the outcome QALY
Model 1 is adjusted for age
Model 2 is adjusted for age + BSI anxiety + BSI depression
Model 3 is adjusted for age + BSI anxiety + BSI depression and is a sensitivity analys
*p < 0.05
**p < 0.01
***p < 0.001including somatic symptoms [41], whereas a UK
cross-sectional study reported that across most health
domains, children and adolescents with ADHD had
poorer scores when compared with samples of children
with diabetes, and a healthy comparison group [42].
These studies highlight the extent that ADHD has on
the health impact on affected individuals.
We analysed the role of ADHD on QALY based on a
one-year horizon. Notably, the proportion of inmates
with a HRQoL over 0.90 (healthy state) was vastly super-
ior amongst those without ADHD. The final adjusteds for Inmates with ADHD Compared with Inmates without
Model 2 Model 3
Beta coef. (se) Beta coef. (se)
− 0.04 (0.01)** − 0.04 (0.01)**
− 0.30 (0.20) –
−0.05 (0.05) − 0.05 (0.05)
− 0.54 (0.25)* − 0.54 (0.25)*
− 0.03 (0.12) − 0.03 (0.12)
− 0.05 (0.04) −0.06 (0.04)
− 0.20 (0.05)*** − 0.20 (0.05)***
− 0.02 (0.07) −0.02 (0.07)
− 0.13(0.04)*** − 0.10 (0.04)*
‘don’t know’ answers. The third column includes the sensitivity analysis, in
ting for ‘don’t know’ answers
is of the sample without correction for ‘don’t know’ answers
Table 4 Three-month Medical and Prison Costs for All 390 Inmates
Cost(£)/unit Median cost over 3 months (£) Inter-quartile range (£)
Medical costs per inmate
General practitioner 121 242 242
Physical health nurse 74.3 74.3 74.3
Mental health nurse 78.5 78.5 78.5
Addiction nurse 78.5 78.5 78.5
Nursing othera 74.3 0 0
Psychiatrist 148.6 0 0
Psychologist 142.2 0 0
Podiatrist 34 0 0
Oral health 87 0 0
Other health visitb 87 0 0
Hospital outpatient 125 0 0
Prison costs per inmate
Activities non-attendancec 38.2 0 76.4
Observation leveld 13.3 0 0
Adjudicationse 21.4 0 0
Critical incidentsd 13.3 0 0
Overall medical costs – 464.9 488.3
Overall prison costs – 34.7 76.4
Overall medical and prison costs – 503.1 532.6
Notes: Cost per unit is defined as cost per inmate for each visit. Median medical costs were calculated from data collected from medical records covering the
3 months prior to interview
aIncludes Hepatitis C, Harm reduction, and Smoking cessation nursing staff
bIncludes any other recorded health visits, e.g. Well-man clinic
cIncludes all missed prison therapeutic and other activities per inmate
dCalculated by time spent and number of prison staff involved (based on average hourly pay rate)
eCalculated by time spent and number of prison staff involved in any adjudication process (estimated 15 min. Per process)
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duced a 0.13 difference in QALY, four-fold above the
0.03 clinically relevant threshold estimated by the instru-
ment developers [26]. QALY based on inmates’ one-year
health utility scores for those with ADHD were signifi-
cantly lower than those without ADHD. Poorer specific
health attribute scores on vision and mobility indicate
that inmates with ADHD have significantly compro-
mised health states that go beyond of those more usually
expected (such as emotion and cognition) from the
disorder. Furthermore, health utilities models adjusted
for psychiatric co-morbidity accounted for the variation
of ADHD on emotion aspects, but not on the cognition
attribute, providing an important insight regarding the
contributing factors to impairment amongst inmates
with ADHD.
The significantly poorer vision score among the
ADHD group may relate to their reading difficulties. In
the present study, those diagnosed with ADHD were
over two times more likely to require assistance with
reading the questionnaires than the other participants.
With respect to mobility, the finding that prisoners withADHD have significantly poorer ambulation problems
may reflect that prisoners with ADHD suffer more injur-
ies that hinder their mobility compared with non-ADHD
prisoners. Data obtained from the Danish registry re-
ported that the morbidity rate is nearly three times
higher if you have ADHD, and that 77.7% of unnatural
deaths were accounted for by accidental injury [12].
Additionally, given the higher rates of aggression and
violence in the ADHD population [43], there may be
mobility problems arising from assault.
ADHD is frequently reported to be associated with a
substantial reduction in the quality of life of children
[44] and with increased chronic health problems in
adults [45]. Study results indicate that ADHD impacts
HRQoL with severe effects in emotional and social
domains, and at least moderate effects in physical
domains [46, 47]. Adult inmates in our sample had an
unadjusted HRQoL of less than 0.60. It is likely that un-
diagnosed and untreated ADHD has a cumulative effect
and increases the risk for further health impairments, es-
pecially among imprisoned adults with coexisting mental
health and social problems.
Table 5 Three-month Medical Service Utilisation for Inmates with ADHD (Compared with Inmates without ADHD; n = 96 ADHD,
n = 294 non-ADHD)
Medical service use beta coefficient (se) IRR (95%CI) p
General practitioner 0.19 (0.09) 1.21 (1.00, 1.45) 0.04
Physical health nurse 0.22 (0.10) 1.25 (1.03, 1.50) 0.02
Mental health nursea 0.61 (0.22) 1.84 (1.19, 2.85) 0.01
Addiction nurse −0.11 (0.21) 0.90 (0.59, 1.35) 0.60
Other nurseb − 0.18 (0.54) 0.83 (0.29, 2.40) 0.74
Psychiatrist and Psychologist −0.12 (0.80) 0.89 (0.19, 4.27) 0.89
Oral health 0.93 (1.46) 2.54 (0.14, 44.74) 0.53
Other health related visitc − 1.85 (0.99) 0.16 (0.02, 1.09) 0.06
Hospital outpatient 0.56 (0.54) 1.76 (0.61, 5.04) 0.30
Note: Visits to Podiatrist excluded for n < 10
aIncludes general mental health and psychiatric nursing staff
bIncludes Hepatitis C, Harm reduction, and Smoking cessation nursing staff
cIncludes any other recorded health visits, e.g. Well-man clinic
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viduals with ADHD may be driven by the existence of
co-morbid conditions [48]. In our study, although
co-morbidity played a role in the impact of ADHD on
HRQoL, the association is not entirely explained by
coexisting psychiatric symptoms of anxiety and depres-
sion. Moreover, there was no attenuation on the associ-
ation with the cognitive attribute of the HUI3 on
adjusted models, suggesting a domain-specific link.
Cognitive dysfunction in the form of difficulties allocat-
ing attentional resources [49], response inhibition, and
management of reward are hallmarks of the ADHD
phenotypic expression. These results denote different
paths through which ADHD may impact adverse health
and quality of life, directly through cognitive deficits and
via co-morbid disorders. We therefore provide evidence
of domain-specific and shared contributions to impaired
HRQoL in ADHD.Service use and costs
Health economic studies on the general population re-
port that ADHD (including symptoms of hyperactivity)
is associated with significant economic burden [1, 2];
however, studies focusing exclusively on the economic
impact of ADHD on adult prisoners were not identified.Table 6 Average Costs Model Results and Estimated Marginal Predic
ADHD; n = 96 ADHD, n = 294 non-ADHD)
3 month beta coefficient
Medical Costs 0.25*
Prison Costs 0.25
Total Costs 0.24**
Note: Findings from Generalised Linear Model using gamma error distribution and
*p < 0.05
**p < 0.01A US study of disability claims reported that patients
with ADHD had 2.6 more medical claims than those
without ADHD and that ADHD imposed a significant
financial burden [1]. A recent prospective UK study
reported that preschoolers with high levels of hyper-
activity had a 17-fold increase in overall costs compared
with non-hyperactive controls; costs were mainly driven
by mental health, educational, social, and criminal justice
system service use [2]. A Danish study reported that the
direct medical costs of ADHD patients were relatively
high, whereof mental care and inpatient hospitalizations
accounted for approximately 60% of the costs and medi-
cation use accounted for 13% [50]. Results of one study
demonstrated that public costs (due to mental health,
school services, and the juvenile justice system) are more
than double for youth with ADHD compared with those
without ADHD [51].
Hospital inpatient stays are a significant driver of costs
attributable to ADHD. A retrospective analysis during a
9 year period reported that median hospital inpatient,
hospital outpatient, or ED admission costs for individ-
uals with ADHD were more than double for those
without ADHD [52]. Pharmacotherapy costs are also a
large part of medical costs attributable to ADHD. Medi-
cation costs were reported to account for about 13–38%
of total costs [1, 2, 24, 50, 52, 53]. Psychological therapytions for Inmates with ADHD (Compared with Inmates without
3 month Predicted margin 1 year Predicted margin
£ 135.9 £ 543.6
£ 11.4 £ 45.6
£ 147.5 £ 590
log link function, adjusted for age
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mon important driver of costs, which was essentially not
utilised by the participants of our study.
Our total estimated annual cost of £590 per inmate
with ADHD demonstrates that the costs attributable to
ADHD are relatively high. But because our estimate did
not include costs for hospital stays, medication, and/or
psychological treatment, the total cost estimate therefore
represents a conservative figure.
In our study, costs associated with ADHD were driven
by increased medical service use and not by behavioural
disturbance incidents. This may indicate that costs
related to behavioural incidents were more generally
distributed across the prison sample and due to many
other factors besides having a diagnosis of ADHD.
Service utilisation patterns were restricted to general
medical and nursing services. Low endorsement of en-
gagement with these and other services may have been a
true reflection of the patterns of use in our sample, or of
the Scottish prison system at large. As many resources
were not used, costs remained lower compared with
other studies mentioned.
Because the present study found there were signifi-
cantly greater medical costs but not behaviour-related
prison costs, the cost implication seems to be largely for
the NHS. While the assignment of prisoner medical
costs based on NHS reimbursements may not perfectly
represent prisoners medical costs (possibly over- or
under-estimated), it helped to estimate and interpret
costs using standard more widely used and familiar
terms. There may be, however, variability in the record-
ing of critical incident data, which will be a fundamental
driver of prison costs, leading to increased number of se-
clusions, adjudications, injury costs and potentially staff
sickness. In a previous study conducted in a large prison
in Aberdeen there were highly significant differences
found in aggressive critical incidents between an ADHD
and a non-ADHD group [43]. Hence for some prison
establishments, costs to the prison service may be con-
siderably higher.
Limitations
A key strength of the study is its large sample size and a
methodology in which every participant was clinically
diagnosed using the DIVA-2. Nonetheless, there are sev-
eral limitations.
Because of missing data, some bias may be present in
our analyses of HUI3 specific attribute scores. However,
our models accounted for missing data using a well
established and oft cited method and the sensitivity
analysis on adjusted models allowed us to have confi-
dence in our methods.
Ethnic minority groups and females did not have rep-
resentation in this sample, therefore, it remains unclearwhether these findings may be fully applicable and gen-
eralized to the entire prison population.
ADHD diagnosis was based on self-reported informa-
tion and we did not include informant (e.g. familial)
reports. Recall bias is unaccounted for and may have
been a factor in symptom measures and service use.
Nevertheless, any bias related to under-reporting was
presumed to have similar effects on estimates for both
the ADHD and non-ADHD groups. Other studies have
reported considerably higher rates of critical incidents
[43, 54], and it is likely that prison costs based on these
would be considerably inflated compared with the esti-
mates derived from the present data.
Our extrapolation method (using 3 months of data to
estimate 1 year) may be limited in its accuracy. We used
a one-year horizon for our HRQoL and service use esti-
mates, and more time than this would have conferred
too much uncertainty. Future research should address
measuring utilities over more time, thereby providing a
better foundation of QALY estimates beyond 1 year.
Finally, the opportunity sampling method used may
have introduced selection bias into the results, limit-
ing their generalizability both within the prison and
across other prisons.
Conclusions
Research on HRQoL and costs related to adult ADHD is
limited in the general population and is virtually
non-existent in the prison population. We addressed this
paucity of data on HRQoL, QALY, service utilization,
and costs attributable to ADHD based on 1 year in
prison. We performed HRQoL and cost analyses for
adult prison inmates with ADHD based on a cross-section
of the Scottish prison system in the UK.
Our study provides evidence that HRQoL of life is
considerably poorer in adult male prison inmates with
ADHD, with an adjusted reduction of 0.13 QALY. Af-
fected health attributes extend beyond emotional and
cognitive deficits, suggesting chronic effects of ADHD
on health over the lifespan. ADHD may contribute to
adverse health and quality of life directly through execu-
tive function and cognitive deficits; and co-morbid disor-
ders. Combined costs within prison were significantly
higher for those with ADHD and were driven by medical
expenses. Service utilisation was for the most part lim-
ited to general practitioner services and nursing staff
visits.
Approximately 80% of inmates considered to have
ADHD did not receive a prior diagnosis — indicating
that a significant proportion of adult prison inmates are
inadequately identified and treated. This has policy
implications for both the National Health and the prison
service. There is a need for the prison service to develop
improved awareness about ADHD in adult prisoners,
Young et al. BMC Psychiatry  (2018) 18:210 Page 9 of 11including the clinical and behavoural presentation of
ADHD. There is also a need to introduce a brief and
reliable screen on admission, such as the 6-item
B-BAARS, which has high sensitivity and specificity [25].
Furthermore, there is a need for the NHS to address the
general absence of health service provision for adults
with ADHD in prisons, as prisoners continue presenting
multiple times for their health problems and seem to re-
main mis- or undiagnosed.
In 2015 the Ministry of Justice reported a population
of 77,472 adult male inmates in the UK. Given the
prevalence rate of 25.5% of ADHD among prisoners [55]
and our estimated annual total cost per adult inmate
with ADHD of £590, we estimate a total cost for medical
and behaviour-related prison care of approximately
£11.7 million per year. This cost estimate, however, is
conservative as it is seemingly driven by general medical
expenses and not by critical incidents. There may be
variability in the reporting of critical incidents in
prisons, and prison care costs associated with behav-
ioural disturbances may be much higher in other
establishments.
ADHD is a prevalent mental health disorder, and a
known risk factor for a series of adverse health and so-
cial outcomes. Population studies report the community
(and society at large) bears considerable medical costs
associated with ADHD [22, 23]. Although ADHD is dis-
proportionately prevalent in prison, it is understudied
and inadequately addressed in this context [55, 56].
Our results provide evidence that adult prisoners with
ADHD represent a unique population with unmet needs
and high costs. Given the Swedish study of patients
showing a 32% reduction in criminality for men and 41%
for women during periods when they were receiving
ADHD medication [57], effective identification and treat-
ment of ADHD may have important cost implications.
We recommend directing efforts to increase access to
effective interventions for adult inmates with ADHD.
Setting up provisions for better access to early diagnosis
and treatment is likely to improve inmates’ HRQoL and
decrease impairment related to ADHD symptoms and
associated co-morbidities.Abbreviations
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